NYSEAMERICAN:NBY - NovaBay Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$1.32 +0.06 (+4.76 %)
(As of 03/26/2019 04:00 PM ET)
Previous Close$1.26
Today's Range$1.26 - $1.35
52-Week Range$0.71 - $3.74
Volume33,100 shs
Average Volume23,878 shs
Market Capitalization$22.56 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets non-antibiotic and anti-infective products for the eye care market in the United States, China, and internationally. It offers Avenova, a prescription product for cleansing and removing foreign materials, including microorganisms and debris from skin around the eye; NeutroPhase for wound care market; CelleRx for the aesthetic dermatology market; Aganocide compounds patented synthetic molecules for use against bacteria, viruses, and fungi; auriclosene irrigation solution for urology; and intelli-Case, a device for soft and rigid gas permeable contact lenses. NovaBay Pharmaceuticals, Inc. has collaboration and license agreement with Virbac to develop auriclosene, a proprietary compound for veterinary markets. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is based in Emeryville, California.

Receive NBY News and Ratings via Email

Sign-up to receive the latest news and ratings for NBY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:NBY
CUSIPN/A
Phone+1-510-8998800

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees86
Market Cap$22.56 million
Next Earnings Date3/28/2019 (Confirmed)
OptionableNot Optionable

NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) Frequently Asked Questions

What is NovaBay Pharmaceuticals' stock symbol?

NovaBay Pharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "NBY."

When did NovaBay Pharmaceuticals' stock split? How did NovaBay Pharmaceuticals' stock split work?

NovaBay Pharmaceuticals's stock reverse split before market open on Monday, December 21st 2015. The 1-25 reverse split was announced on Friday, December 11th 2015. The number of shares owned by shareholders was adjusted after the market closes on Friday, December 18th 2015. An investor that had 100 shares of NovaBay Pharmaceuticals stock prior to the reverse split would have 4 shares after the split.

How were NovaBay Pharmaceuticals' earnings last quarter?

NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) issued its quarterly earnings results on Tuesday, November, 14th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.07) by $0.09. The biopharmaceutical company earned $4.09 million during the quarter, compared to analysts' expectations of $4.69 million. View NovaBay Pharmaceuticals' Earnings History.

When is NovaBay Pharmaceuticals' next earnings date?

NovaBay Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 28th 2019. View Earnings Estimates for NovaBay Pharmaceuticals.

What guidance has NovaBay Pharmaceuticals issued on next quarter's earnings?

NovaBay Pharmaceuticals updated its FY 2019 earnings guidance on Monday, January, 7th. The company provided EPS guidance of for the period. The company issued revenue guidance of $16-16.5 million, compared to the consensus revenue estimate of $16.74 million.NovaBay Pharmaceuticals also updated its FY 2018 guidance to EPS.

What price target have analysts set for NBY?

3 analysts have issued twelve-month target prices for NovaBay Pharmaceuticals' shares. Their forecasts range from $1.50 to $4.00. On average, they expect NovaBay Pharmaceuticals' share price to reach $2.75 in the next twelve months. This suggests a possible upside of 108.3% from the stock's current price. View Analyst Price Targets for NovaBay Pharmaceuticals.

What is the consensus analysts' recommendation for NovaBay Pharmaceuticals?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NovaBay Pharmaceuticals in the last year. There are currently 3 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for NovaBay Pharmaceuticals.

What are Wall Street analysts saying about NovaBay Pharmaceuticals stock?

Here are some recent quotes from research analysts about NovaBay Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing innovative product candidates targeting the treatment or prevention of a wide range of infections in hospital and non-hospital environments. NovaBay has discovered and is developing a class of antimicrobial compounds, which it has named Aganocide compounds, which are based upon small molecules that are generated by white blood cells that defend the body against invading pathogens. NovaBay believes that Aganocide compounds could form a platform on which to create a variety of products to address differing needs in the treatment and prevention of bacterial and viral infections, including Methicillin-Resistant Staphylococcus aureus. " (3/14/2019)
  • 2. HC Wainwright analysts commented, "Our 12-month price target is derived from a market value of the firm at $31M, which includes a discounted cash flow based asset value for Avenova, using 15% discount rate and 2% terminal growth rate." (3/13/2019)

Has NovaBay Pharmaceuticals been receiving favorable news coverage?

Media coverage about NBY stock has been trending somewhat negative recently, according to InfoTrie Sentiment. The research firm identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. NovaBay Pharmaceuticals earned a news impact score of -1.4 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the immediate future.

Who are some of NovaBay Pharmaceuticals' key competitors?

What other stocks do shareholders of NovaBay Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NovaBay Pharmaceuticals investors own include Opko Health (OPK), AEterna Zentaris (AEZS), Synergy Pharmaceuticals (SGYP), CorMedix (CRMD), Tetraphase Pharmaceuticals (TTPH), Amicus Therapeutics (FOLD), TherapeuticsMD (TXMD), Progenics Pharmaceuticals (PGNX), Ekso Bionics (EKSO) and CTI BioPharma (CTIC).

Who are NovaBay Pharmaceuticals' key executives?

NovaBay Pharmaceuticals' management team includes the folowing people:
  • Mr. Justin M. Hall, Interim Pres, CEO, Gen. Counsel & Corp. Sec. (Age 41)
  • Mr. Jason Raleigh, Interim CFO, Treasurer & Corp. Controller (Age 42)
  • Dr. David W. Stroman, Sr. VP of Ophthalmic Product Devel. & Chair of Ophthalmology Advisory Board (Age 74)

How do I buy shares of NovaBay Pharmaceuticals?

Shares of NBY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is NovaBay Pharmaceuticals' stock price today?

One share of NBY stock can currently be purchased for approximately $1.32.

How big of a company is NovaBay Pharmaceuticals?

NovaBay Pharmaceuticals has a market capitalization of $22.56 million. NovaBay Pharmaceuticals employs 86 workers across the globe.

What is NovaBay Pharmaceuticals' official website?

The official website for NovaBay Pharmaceuticals is http://novabay.com/.

How can I contact NovaBay Pharmaceuticals?

NovaBay Pharmaceuticals' mailing address is 2000 Powell St Ste 1150, EMERYVILLE, CA 94608-1804, United States. The biopharmaceutical company can be reached via phone at +1-510-8998800.


MarketBeat Community Rating for NovaBay Pharmaceuticals (NYSEAMERICAN NBY)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  154 (Vote Outperform)
Underperform Votes:  138 (Vote Underperform)
Total Votes:  292
MarketBeat's community ratings are surveys of what our community members think about NovaBay Pharmaceuticals and other stocks. Vote "Outperform" if you believe NBY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NBY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/26/2019 by MarketBeat.com Staff

Featured Article: Special Dividends

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel